NVAX: Major pharma partnerships, Matrix-M expansion, and global commercialization drive future growth
The company shifted from a single-product focus to global technology licensing, securing major pharma partnerships and reducing costs. Matrix-M is used in infectious disease and oncology, with new data expected. Global commercialization, especially via Sanofi, supports a strong outlook for combinat…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.